GlassScriptPhysician profile
Mark A Aziz
NPI 1407003403
$8,545.39
in general payments reported to CMS, 2019-2025
22 companies · $988 in 2025
The $988 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,359 · 2020: $117 · 2021: $245 · 2022: $271 · 2023: $946 · 2024: $2,619 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,405 · Travel and Lodging: $1,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,405.00 |
| Travel and Lodging | $1,149.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,997.55 | 2019-2025 | General - Structural Heart, Eluvia, Rotapro |
| Edwards Lifesciences Corporation | $2,684.17 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $976.80 | 2019-2025 | Xience Skypoint, Ultreon, Xience Sierra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $388.89 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $233.54 | 2020-2025 | Camzyos, Eliquis |
| Abiomed | $221.90 | 2019-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $202.14 | 2019-2024 | |
| Cardiva Medical, INC. | $180.74 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Angiodynamics, INC. | $169.59 | 2024-2025 | Alphavac |
| Terumo Medical Corporation | $160.22 | 2024 | Heartrail, Glidewire, Glidesheath Slender |
| Pfizer INC. | $58.07 | 2019-2021 | |
| Biosense Webster, INC. | $39.00 | 2024-2025 | Carto 3 |
| Janssen Pharmaceuticals, INC | $34.28 | 2019-2022 | |
| Philips North America LLC | $31.49 | 2025 | Elca, Coronary Other |
| Amgen INC. | $31.21 | 2024 | Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bolton Medical INC | $27.26 | 2025 | Relay Thoracic Stent-Graft With Plus Delivery System, Thoraflex Hybrid, Treo Abdominal Stent-Graft System |
| Astrazeneca Pharmaceuticals LP | $23.53 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.76 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.85 | 2019 | |
| Inari Medical, INC. | $17.80 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cardiovascular Systems INC. | $15.44 | 2022 | |
| Medtronic Vascular, INC. | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.